Posted by Michael Wonder on 03 Jun 2024
Paediatric rare disease drug Qarziba gets green light for coverage
30 May 2024 - The Health Insurance Review and Assessment Service (HIRA) held its fourth Cancer Disease Review Committee (CDRC) on Wednesday and disclosed the results of its deliberations on the reimbursement standards for anti-cancer drugs.
At the CDRC meeting, Recordati Korea’s Qarziba (dinutuximab), a new drug for treating rare paediatric diseases, set its reimbursement standards as a pilot project for simultaneous approval, evaluation, and negotiation.
